Stibium Metallicum Praeparatum 6x Versus Placebo in the Prevention of Paclitaxel-induced Peripheral Neurotoxicity

PHASE3Not yet recruitingINTERVENTIONAL
Enrollment

120

Participants

Timeline

Start Date

August 31, 2025

Primary Completion Date

August 31, 2026

Study Completion Date

August 31, 2026

Conditions
Chemotherapy Induced Peripheral Neuropathy (CIPN)
Interventions
DRUG

Stibium metallicum praeparatum 6x

Stibium metallicum praeparatum 6x will be administered with subcutaneous injections 3 times a week at 1 ampoule at 1 mL during the chemotherapy and shall be continued during 6 weeks after the end of chemotherapy . The first injection will be administered on the day of the first dose of chemotherapy, before the injection of the first dose of chemotherapy.

DRUG

Placebo

Placebo will be administered with subcutaneous injections 3 times a week at 1 ampoule at 1 mL during the chemotherapy and shall be continued during 6 weeks after the end of chemotherapy . The first injection will be administered on the day of the first dose of chemotherapy, before the injection of the first dose of chemotherapy.

All Listed Sponsors
collaborator

Insel Gruppe AG, University Hospital Bern

OTHER

collaborator

Hospital of Thun

UNKNOWN

collaborator

Tumor- und Brustzentrum ZeTuP St.Gallen

UNKNOWN

collaborator

Gesundheitszentrum Fricktal AG

UNKNOWN

collaborator

Kantonsspital Winterthur KSW

OTHER

collaborator

Kantonsspital Graubünden

OTHER

collaborator

Kantonsspital Aarau

OTHER

lead

University of Bern

OTHER

NCT04715542 - Stibium Metallicum Praeparatum 6x Versus Placebo in the Prevention of Paclitaxel-induced Peripheral Neurotoxicity | Biotech Hunter | Biotech Hunter